4 research outputs found
Phase III study of Ribociclib (LEE011) plus Fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have received no or only one line of prior endocrine treatment : MONALEESA-3
Full text linkpeer reviewe
Comparative pharmacokinetic studies of borneol in mouse plasma and brain by different administrations
No full text
